Genetically-informed treatment for advanced and metastatic prostate cancer

Alicia K. Morgans; Brittany M. Szymaniak

Genetically-informed treatment for advanced and metastatic prostate cancer

Alicia K. Morgans, Brittany M. Szymaniak

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The landscape of genetic testing for prostate cancer is rapidly evolving. There is increasing evidence that individuals with germline mutations in DNA-repair genes are more responsive to targeted therapies. Due to potential implications for treatment, these genes should be taken into consideration when determining the scope of genetic testing.

Original language	English (US)
Pages (from-to)	54-56
Number of pages	3
Journal	The Canadian journal of urology
Volume	26
Issue number	5
State	Published - Oct 1 2019

ASJC Scopus subject areas

Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{dbf7a6435a954d1b8c6a702703dc2e43,

title = "Genetically-informed treatment for advanced and metastatic prostate cancer",

abstract = "The landscape of genetic testing for prostate cancer is rapidly evolving. There is increasing evidence that individuals with germline mutations in DNA-repair genes are more responsive to targeted therapies. Due to potential implications for treatment, these genes should be taken into consideration when determining the scope of genetic testing.",

author = "Morgans, {Alicia K.} and Szymaniak, {Brittany M.}",

year = "2019",

month = oct,

day = "1",

language = "English (US)",

volume = "26",

pages = "54--56",

journal = "Canadian Journal of Urology",

issn = "1195-9479",

publisher = "Canadian Journal of Urology",

number = "5",

}

TY - JOUR

T1 - Genetically-informed treatment for advanced and metastatic prostate cancer

AU - Morgans, Alicia K.

AU - Szymaniak, Brittany M.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - The landscape of genetic testing for prostate cancer is rapidly evolving. There is increasing evidence that individuals with germline mutations in DNA-repair genes are more responsive to targeted therapies. Due to potential implications for treatment, these genes should be taken into consideration when determining the scope of genetic testing.

AB - The landscape of genetic testing for prostate cancer is rapidly evolving. There is increasing evidence that individuals with germline mutations in DNA-repair genes are more responsive to targeted therapies. Due to potential implications for treatment, these genes should be taken into consideration when determining the scope of genetic testing.

UR - http://www.scopus.com/inward/record.url?scp=85073606775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073606775&partnerID=8YFLogxK

M3 - Article

C2 - 31629435

AN - SCOPUS:85073606775

SN - 1195-9479

VL - 26

SP - 54

EP - 56

JO - Canadian Journal of Urology

JF - Canadian Journal of Urology

IS - 5

ER -

Genetically-informed treatment for advanced and metastatic prostate cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this